TY - JOUR
T1 - Absence of PKR attenuates the anti-HSV-1 activity of an adenoviral vector expressing murine IFN-β
AU - Al-Khatib, Khaldun
AU - Williams, Bryan R.G.
AU - Silverman, Robert H.
AU - Halford, William P.
AU - Carr, Daniel J.J.
PY - 2002/1/1
Y1 - 2002/1/1
N2 - A study was undertaken to evaluate the efficacy of an adenoviral vector containing the murine interferon-β (IFN-β) transgene (Ad:IFN-β) against herpes simplex virus type 1 (HSV-1) infection in two transduced cell lines. The transduction of the adenoviral vector efficiency, ranging from 2% to 100%, was dependent on the multiplicity of infection (moi) (0.4-50 plaque-forming units [pfu]/cell). Supernatants from cells transduced with the Ad:IFN-β but not the adenoviral null vector (Ad:Null) contained biologically active IFN-β (6.6-106 U/ml depending on the moi). Cells transduced with the Ad:IFN-β displayed up to 25-fold reduction in viral titers compared with cells transduced with the Ad:Null or nontransduced cell controls. The suppression in viral titer correlated with a reduction in viral gene (α, β, and γ) and protein expression. The expression of IFN-β-responsive genes, including protein kinase R (PKR) and 2′, 5′-oligoadenylate synthetase (OAS), were significantly elevated in the Ad:IFN-β-transduced cells by 12-fold and 25-fold, respectively. However, after infection with HSV-1, a transient but significant drop in PKR but not OAS gene expression was observed 10 h postinfection. The absence of PKR but not RNase L significantly attenuated the antiviral efficacy of the transgene. Collectively, these results illustrate the feasibility of employing a viral vector to deliver a potent antiviral gene to targeted cells without any obvious detriment to the vector itself and support an important role for PKR as a mediator of the anti-HSV-1 activity of type I IFN.
AB - A study was undertaken to evaluate the efficacy of an adenoviral vector containing the murine interferon-β (IFN-β) transgene (Ad:IFN-β) against herpes simplex virus type 1 (HSV-1) infection in two transduced cell lines. The transduction of the adenoviral vector efficiency, ranging from 2% to 100%, was dependent on the multiplicity of infection (moi) (0.4-50 plaque-forming units [pfu]/cell). Supernatants from cells transduced with the Ad:IFN-β but not the adenoviral null vector (Ad:Null) contained biologically active IFN-β (6.6-106 U/ml depending on the moi). Cells transduced with the Ad:IFN-β displayed up to 25-fold reduction in viral titers compared with cells transduced with the Ad:Null or nontransduced cell controls. The suppression in viral titer correlated with a reduction in viral gene (α, β, and γ) and protein expression. The expression of IFN-β-responsive genes, including protein kinase R (PKR) and 2′, 5′-oligoadenylate synthetase (OAS), were significantly elevated in the Ad:IFN-β-transduced cells by 12-fold and 25-fold, respectively. However, after infection with HSV-1, a transient but significant drop in PKR but not OAS gene expression was observed 10 h postinfection. The absence of PKR but not RNase L significantly attenuated the antiviral efficacy of the transgene. Collectively, these results illustrate the feasibility of employing a viral vector to deliver a potent antiviral gene to targeted cells without any obvious detriment to the vector itself and support an important role for PKR as a mediator of the anti-HSV-1 activity of type I IFN.
UR - http://www.scopus.com/inward/record.url?scp=0036405429&partnerID=8YFLogxK
U2 - 10.1089/107999002760274872
DO - 10.1089/107999002760274872
M3 - Article
C2 - 12396725
SN - 1079-9907
VL - 22
SP - 861
EP - 871
JO - Journal of Interferon and Cytokine Research
JF - Journal of Interferon and Cytokine Research
IS - 8
ER -